Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Conventional chemotherapeutics have been developed into clinically useful agents based
on their ability to preferentially kill malignant cells, generally owing to their elevated …
on their ability to preferentially kill malignant cells, generally owing to their elevated …
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
DR Principe, SD Kamath, M Korc, HG Munshi - Pharmacology & …, 2022 - Elsevier
Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for several
malignancies. While the use of single-agent or combined ICIs has achieved acceptable …
malignancies. While the use of single-agent or combined ICIs has achieved acceptable …
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
S Sugawara, JS Lee, JH Kang, HR Kim, N Inui, T Hida… - Annals of …, 2021 - Elsevier
Background This international, randomized, double-blind phase III study (ONO-4538-
52/TASUKI-52) evaluated nivolumab with bevacizumab and cytotoxic chemotherapy as first …
52/TASUKI-52) evaluated nivolumab with bevacizumab and cytotoxic chemotherapy as first …
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
The number of clinical protocols testing combined therapies including immune check-point
inhibitors and platinum salts is currently increasing in lung cancer treatment, however …
inhibitors and platinum salts is currently increasing in lung cancer treatment, however …
Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor …
L Tu, R Guan, H Yang, Y Zhou, W Hong… - … journal of cancer, 2020 - Wiley Online Library
Immune checkpoint molecules have been identified as crucial regulators of the immune
response, which motivated the emergence of immune checkpoint‐targeting therapeutic …
response, which motivated the emergence of immune checkpoint‐targeting therapeutic …
FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell–mediated bladder cancer immune surveillance
W Jing, G Wang, Z Cui, G Xiong, X Jiang, Y Li, W Li… - Cancer research, 2022 - AACR
Fibroblast growth factor receptor 3 (FGFR3) is frequently activated by mutation or
overexpression, and it is a validated therapeutic target in urothelial carcinoma (UC) of the …
overexpression, and it is a validated therapeutic target in urothelial carcinoma (UC) of the …
Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1
TW Chen, WZ Hung, SF Chiang, WTL Chen, TW Ke… - Cancer letters, 2022 - Elsevier
TGFβ contributes to chemoresistance in advanced colorectal cancer (CRC) via diverse
immune-microenvironment mechanisms. Here, we found that cancer cell autonomous TGFβ …
immune-microenvironment mechanisms. Here, we found that cancer cell autonomous TGFβ …
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): which are the involved players?
G Lamberti, M Sisi, E Andrini, A Palladini, F Giunchi… - Cancers, 2020 - mdpi.com
Simple Summary Immunotherapy against PD-1/PD-L1 dramatically improved outcomes in
non-small cell lung cancer patients. These treatments are more effective the higher the …
non-small cell lung cancer patients. These treatments are more effective the higher the …
Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
J Mo, X Hu, L Gu, B Chen, PA Khadaroo… - World journal of surgical …, 2020 - Springer
Background Immune checkpoint inhibitors, which are a milestone in anti-cancer therapy,
have been applied in the treatment of multiple malignancies. Real-world data have …
have been applied in the treatment of multiple malignancies. Real-world data have …
[HTML][HTML] PD-L1 testing in non-small cell lung cancer: past, present, and future
H Kim, JH Chung - Journal of pathology and translational medicine, 2019 - ncbi.nlm.nih.gov
Blockade of the programmed cell death-1 (PD-1) axis has already been established as an
effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for …
effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for …